5,632
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

, , , , , , & show all
Pages 2612-2624 | Received 02 Mar 2021, Accepted 03 May 2021, Published online: 23 Jun 2021